Developer docs
API playgroundTry for free, no card

Search company profiles

Frequency Therapeutics

Full company profile

uuid000567i

Namestring
Frequency Therapeutics
Websiteurl
frequencytx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Frequency Therapeutics is a clinical-stage biotechnology company founded in 2015 and based in Lexington, Massachusetts, that develops small-molecule drugs intended to activate progenitor cells in vivo to restore damaged or degraded tissue. Its core technical premise is the proprietary activation of resident progenitor-cell populations, with publicly disclosed therapeutic exploration spanning sensorineural hearing loss (its flagship program), type 1 diabetes (under a 2018 partnership-style funding from Breakthrough T1D), and additional indications supported by a 2018 grant from the U.S. Department of War.

The company historically generated revenue through milestone-driven collaboration and grant arrangements rather than product sales, with reported top lines of roughly $37M in 2020 and $14M in 2021 before ceasing disclosure in 2022. Across the 2018-2022 period the company raised approximately $180M+ in cumulative disclosed equity and grant funding from a mix of specialist biotech investors (Perceptive Advisors, RTW Investments, Wasatch Advisors) and strategic backers (Taiwania Capital, Korea Investment Partners, Yonjin Venture), alongside non-dilutive awards from the U.S. Department of War and Breakthrough T1D.

Operating losses exceeded $80M in both 2021 and 2022, headcount is reported at 11-50 employees, the company is listed as delisted from NASDAQ (symbol FREQ), and its corporate website is currently unreachable (HTTP 522). These signals collectively indicate the company has materially contracted from its pre-2022 operating scale and is no longer functioning as an active commercial biotech.

Short descriptiontext

Frequency Therapeutics is a Lexington, Massachusetts-based, now-delisted clinical-stage biotech developing small-molecule drugs designed to activate progenitor cells to regenerate damaged tissue across hearing loss and other indications.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
small molecule therapeutics, progenitor cell activation, regenerative medicine, hearing loss treatment, disease-modifying drugs
Industry1 code
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
Product category
Regenerative Medicine Pharmaceuticals
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Frequency Therapeutics develops small molecule drugs designed to activate progenitor cells within the body to restore healthy tissue. The company's lead therapeutic approach targets hearing loss through regeneration of inner ear hair cells, leveraging its proprietary Progenitor Cell Activation (PCA) platform to create disease-modifying treatments.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1FX-322
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing small-molecule therapeutics that target neural progenitor cell biology for hearing loss and remyelination — overlapping mechanism (small-molecule progenitor activation) and overlapping indications (MS) with Frequency's post-pivot focus.

TypeDirect peer
Description

Small-molecule developer with a clinical program in progressive MS and remyelination (VSA-001 / PIPE-307) — directly comparable to Frequency's FX-001 in modality, target biology, and patient population.

TypeDirect peer
Description

Pre-acquisition, Decibel Therapeutics pursued small-molecule and gene-therapy approaches to hearing restoration — the same indication Frequency's FX-322 targeted prior to its divestiture to Astellas.

4Otonomy
TypeDirect peer
Description

Clinical-stage company developing therapeutics for ear disorders and hearing loss — historically a direct competitor to Frequency's FX-322 program in otology indications.

5Athersys
TypeEmerging player
Description

Cell-therapy and regenerative-medicine developer (MultiStem) targeting neurological and inflammatory indications — shares Frequency's regenerative-medicine thesis and small-cap clinical-stage risk profile.

TypeEmerging player
Description

Cell-replacement and regenerative-medicine company developing allogeneic cell therapies for CNS indications — comparable in regenerative-medicine modality and clinical-stage CNS focus to Frequency's remyelination effort.

TypeBroad incumbent
Description

CNS-focused commercial-stage biopharma with a neurological-disease pipeline — a broader incumbent illustrating the strategic and clinical benchmarks Frequency's CNS remyelination program must reach to compete for adoption.

TypeBroad incumbent
Description

Large-cap biopharma pursuing small-molecule approaches to serious diseases (including cell/gene editing for sickle cell and beta-thalassemia) — sets the gold standard for small-molecule regenerative-medicine execution that Frequency aspires to.

TypeDirect peer
Description

Clinical-stage company developing therapeutics for inner-ear and hearing disorders — a direct historical peer in the otology space where Frequency operated prior to its FX-322 failure.

TypeEmerging player
Description

Small clinical-stage CNS-focused biotech developing small-molecule therapeutics — comparable in scale, stage, and CNS-focused small-molecule positioning to Frequency's post-pivot profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors23 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequency Therapeutics

Regenerative Medicine Pharmaceuticalsfrequencytx.com

Frequency Therapeutics is a Lexington, Massachusetts-based, now-delisted clinical-stage biotech developing small-molecule drugs designed to activate progenitor cells to regenerate damaged tissue across hearing loss and other indications.

What Frequency Therapeutics does

Frequency Therapeutics is a clinical-stage biotechnology company founded in 2015 and based in Lexington, Massachusetts, that develops small-molecule drugs intended to activate progenitor cells in vivo to restore damaged or degraded tissue. Its core technical premise is the proprietary activation of resident progenitor-cell populations, with publicly disclosed therapeutic exploration spanning sensorineural hearing loss (its flagship program), type 1 diabetes (under a 2018 partnership-style funding from Breakthrough T1D), and additional indications supported by a 2018 grant from the U.S. Department of War.

The company historically generated revenue through milestone-driven collaboration and grant arrangements rather than product sales, with reported top lines of roughly $37M in 2020 and $14M in 2021 before ceasing disclosure in 2022. Across the 2018-2022 period the company raised approximately $180M+ in cumulative disclosed equity and grant funding from a mix of specialist biotech investors (Perceptive Advisors, RTW Investments, Wasatch Advisors) and strategic backers (Taiwania Capital, Korea Investment Partners, Yonjin Venture), alongside non-dilutive awards from the U.S. Department of War and Breakthrough T1D.

Operating losses exceeded $80M in both 2021 and 2022, headcount is reported at 11-50 employees, the company is listed as delisted from NASDAQ (symbol FREQ), and its corporate website is currently unreachable (HTTP 522). These signals collectively indicate the company has materially contracted from its pre-2022 operating scale and is no longer functioning as an active commercial biotech.

Frequency Therapeutics firmographics

Firmographics
Name
Frequency Therapeutics
Website
https://frequencytx.com
Company type
Private
Founded year
2015
Headcount range
11–50 employees
Short description
Frequency Therapeutics is a Lexington, Massachusetts-based, now-delisted clinical-stage biotech developing small-molecule drugs designed to activate progenitor cells to regenerate damaged tissue across hearing loss and other indications.
Ownership category
akta.pro rank

Frequency Therapeutics industry classification

Industry
Product category
Regenerative Medicine Pharmaceuticals
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Small molecule therapeutics
  • Progenitor cell activation
  • Regenerative medicine
  • Hearing loss treatment
  • Disease-modifying drugs

Where Frequency Therapeutics is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Markets served

Frequency Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Frequency Therapeutics product offering

Product offering

Core offering

Frequency Therapeutics develops small molecule drugs designed to activate progenitor cells within the body to restore healthy tissue. The company's lead therapeutic approach targets hearing loss through regeneration of inner ear hair cells, leveraging its proprietary Progenitor Cell Activation (PCA) platform to create disease-modifying treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • FX-322

Companies that use Frequency Therapeutics

Customer profile

Ideal customer profiles1 record

Frequency Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Frequency Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights3 records

Frequency Therapeutics competitors and assessment

Company assessment

Direct peers

  • Pipeline Therapeutics: Clinical-stage biotech developing small-molecule therapeutics that target neural progenitor cell biology for hearing loss and remyelination — overlapping mechanism (small-molecule progenitor activation) and overlapping indications (MS) with Frequency's post-pivot focus.
  • Contineum Therapeutics: Small-molecule developer with a clinical program in progressive MS and remyelination (VSA-001 / PIPE-307) — directly comparable to Frequency's FX-001 in modality, target biology, and patient population.
  • Decibel Therapeutics: Pre-acquisition, Decibel Therapeutics pursued small-molecule and gene-therapy approaches to hearing restoration — the same indication Frequency's FX-322 targeted prior to its divestiture to Astellas.
  • Otonomy: Clinical-stage company developing therapeutics for ear disorders and hearing loss — historically a direct competitor to Frequency's FX-322 program in otology indications.
  • Auris Medical: Clinical-stage company developing therapeutics for inner-ear and hearing disorders — a direct historical peer in the otology space where Frequency operated prior to its FX-322 failure.

Emerging players

  • Athersys: Cell-therapy and regenerative-medicine developer (MultiStem) targeting neurological and inflammatory indications — shares Frequency's regenerative-medicine thesis and small-cap clinical-stage risk profile.
  • Lineage Cell Therapeutics: Cell-replacement and regenerative-medicine company developing allogeneic cell therapies for CNS indications — comparable in regenerative-medicine modality and clinical-stage CNS focus to Frequency's remyelination effort.
  • VistaGen Therapeutics: Small clinical-stage CNS-focused biotech developing small-molecule therapeutics — comparable in scale, stage, and CNS-focused small-molecule positioning to Frequency's post-pivot profile.

Broad incumbents

  • Acadia Pharmaceuticals: CNS-focused commercial-stage biopharma with a neurological-disease pipeline — a broader incumbent illustrating the strategic and clinical benchmarks Frequency's CNS remyelination program must reach to compete for adoption.
  • Vertex Pharmaceuticals: Large-cap biopharma pursuing small-molecule approaches to serious diseases (including cell/gene editing for sickle cell and beta-thalassemia) — sets the gold standard for small-molecule regenerative-medicine execution that Frequency aspires to.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Frequency Therapeutics social profiles

Digital presence

Frequency Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Frequency Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Frequency Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Frequency Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frequency Therapeutics

What does Frequency Therapeutics do?

Frequency Therapeutics develops small molecule drugs designed to activate progenitor cells within the body to restore healthy tissue. The company's lead therapeutic approach targets hearing loss through regeneration of inner ear hair cells, leveraging its proprietary Progenitor Cell Activation (PCA) platform to create disease-modifying treatments.

When was Frequency Therapeutics founded?

Frequency Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Frequency Therapeutics based?

Frequency Therapeutics is headquartered in Lexington, United States, in the North America region.

Who are Frequency Therapeutics's main competitors?

Direct peers on record are Pipeline Therapeutics, Contineum Therapeutics, Decibel Therapeutics, Otonomy and Auris Medical. Emerging players are Athersys, Lineage Cell Therapeutics and VistaGen Therapeutics. Broad incumbents are Acadia Pharmaceuticals and Vertex Pharmaceuticals.

Does Frequency Therapeutics have an API?

No public API is recorded for Frequency Therapeutics.

What industry is Frequency Therapeutics in?

Frequency Therapeutics's product category is Regenerative Medicine Pharmaceuticals. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestSecurities Class Action Risks and Investor Protection in Volatile Biotech Stocks: Navigating Legal and Financial ImplicationsBiotech firms faced 21.1% of 2024 federal securities lawsuits, with cases like Frequency Therapeutics and Quantum BioPharma cited. Litigated biotech stocks underperformed the S&P 500 by 12% annually, and experts urge transparency and diversification to mitigate risks.GlobeNewswireAdvancements in Sensorineural Hearing Loss Clinical Trial Pipeline as 20+ Companies Pave the Way for Future Solutions | DelveInsightDelveInsight released its 'Sensorineural Hearing Loss Pipeline Insight 2024' report, highlighting that over 20 companies are actively developing therapies for sensorineural hearing loss. The article details recent clinical developments and partnerships involving key players such as Astellas Pharma, Frequency Therapeutics, Sensorion, Sound Pharmaceuticals, and Akouos Inc., with specific updates on drug trials like SENS-401 and SPI-1005.GlobeNewswireUPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 MillionKorro Bio completed its merger with Frequency Therapeutics, with shares trading under 'KRRO' on Nasdaq starting November 6, 2023. The company raised $117 million in a private placement and expects $170 million in cash to fund operations into 2026, including advancing its lead AATD program.GlobeNewswireKorro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 MillionKorro Bio completed its merger with Frequency Therapeutics, with shares trading on Nasdaq under 'KRRO' on November 6, 2023. The company raised $117 million in a private placement and expects $170 million in cash to fund operations into 2026. Its lead program in alpha-1 antitrypsin deficiency has shown up to 85% increase in normal A1AT protein in preclinical studies.KorrobioKorro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million – Korro Bio, Inc.Korro Bio, Inc. has completed its merger with Frequency Therapeutics, Inc., forming a combined biopharmaceutical company focused on RNA editing technologies. The transaction was accompanied by an $117 million private placement co-led by Surveyor Capital and Cormorant Asset Management, bringing post-transaction cash reserves to approximately $170 million to fund operations through 2026.GlobeNewswireKorro Bio Announces Appointment of Tim Pearson to Board of Directors Upon Closing of the Proposed Merger and Promotion of Todd Chappell to Chief Operating OfficerKorro Bio announced the appointment of Tim Pearson to its board and the promotion of Todd Chappell to chief operating officer, effective upon closing of its proposed merger with Frequency Therapeutics. The merger, expected to close in Q4 2023, includes a concurrent financing of approximately $117 million. The company anticipates nominating its first development candidate in AATD later this year.BenzingaWhy Are Frequency Therapeutics Shares Surging TodayKorro Bio Inc and Frequency Therapeutics Inc announced an all-stock merger transaction, under which Frequency Therapeutics stockholders will receive newly issued shares of Korro Bio. Frequency Therapeutics has discontinued its remyelination program for Multiple Sclerosis as part of the deal. Korro Bio has secured $117 million in concurrent financing, with the combined company expected to have approximately $170 million in cash and a runway into 2026, while FREQ shares surged 54.80% to $0.62.Business Wire BlogKorro Bio and Frequency Therapeutics Announce Merger AgreementKorro Bio and Frequency Therapeutics have entered into a definitive merger agreement to combine their operations, with the resulting entity operating under Korro Bio's name and focusing on its RNA editing portfolio. The transaction includes a concurrent $117 million financing led by Surveyor Capital and Cormorant Asset Management, bringing the combined company's cash balance to approximately $170 million upon closing in the fourth quarter of 2023.Wayback MachineKorro Bio and Frequency Therapeutics Announce Merger Agreement – Korro BioKorro Bio and Frequency Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction, with the resulting entity operating under Korro Bio and focusing on its RNA editing portfolio. The combined company is expected to have approximately $170 million in cash at close, supported by a concurrent $117 million financing, providing a runway through 2026. The merger is scheduled to close in the fourth quarter of 2023, subject to stockholder approval.MarketScreenerKorro Bio, Inc. entered into a definitive merger agreement to acquire Frequency Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.Korro Bio, Inc. has entered into a definitive merger agreement to acquire Frequency Therapeutics, Inc. through a reverse merger transaction involving the company's shareholders. This strategic acquisition allows Korro Bio to expand its portfolio of genetic medicines based on RNA editing technology. The deal represents a significant corporate development for both biopharmaceutical entities involved in the transaction.